Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 28Unknown 16Recruiting 14Terminated 12Active not recruiting 9Withdrawn 6Not yet recruiting 2Approved for marketing 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6Gastrointestinal 4Genitourinary 3Breast 3Sarcoma 2Other solid neoplasm 1Lymphoid 1CNS 1

Conditions

Ovarian Neoplasms 5Fallopian Tube Neoplasms 2Uterine Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Endometrial Neoplasms 1Cystadenocarcinoma, Serous 1Breast Neoplasms 1

Interventions

Paclitaxel 20Carboplatin 20Bevacizumab 13Radiotherapy 12Cisplatin 11Cyclophosphamide 8olaparib 6niraparib 6Taxes 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Biopsy 5talazoparib 4dostarlimab 4aldesleukin 4Specimen Handling 4Fulvestrant 4Doxorubicin 4fludarabine 3atezolizumab 3Topotecan 3Radiation 3NVP-BKM120 3Methods 3Metformin 3Letrozole 3Hyperthermic Intraperitoneal Chemotherapy 3Early Intervention, Educational 3Colposcopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × niraparib × Gynecologic × Clear all
NCT05672095 2025-05-23

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

City of Hope Medical Center

Phase 1/2 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

AGO Research GmbH

Phase 2 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05289648 2024-12-19

NIREC

Sir Mortimer B. Davis - Jewish General Hospital

Phase EARLY_PHASE1 Withdrawn
Gynecologic

Uterine Neoplasms, Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT06161493 2024-10-15

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

University of Pittsburgh

Phase 1 Withdrawn
Gynecologic

Ovarian Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT03806049 2021-07-15

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Phase 3 Withdrawn
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡